NeurAxis Says Proprietary PENFS Technology Officially Incorporated Into Newly Released Clinical Practice Guidelines Issued By Pediatric Academic Society For Treatment Of FAP In IBS

Author: Benzinga Newsdesk | June 10, 2025 07:03am

• Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBS
• NeurAxis's PENFS technology is the only FDA-cleared or approved treatment that is recommended in the guidelines for pediatrics, enabling momentum for large-scale insurance coverage for IB-Stim®

CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its flagship product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations.

Posted In: NRXS